Elraglusib was developed as a targeted GSK3β inhibitor, and its anticancer effects have been variously attributed to GSK3 inhibition within cancer cells, resulting in abnormal regulation of NF-κB, impaired DNA damage responses, or myc downregulation, and to immunomodulatory effects within NK and T cells (7, 13, 28, 29). This evidence concerns the gene MYC and cancer.